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Abstract: The clonal basis of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
is complex and not fully understood. Next-generation sequencing (NGS), array comparative
genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) were
carried out in matched diagnosis–relapse samples from 13 BCP-ALL patients to identify patterns
of genetic evolution that could account for the phenotypic changes associated with disease relapse.
The integrative genomic analysis of aCGH, MLPA and NGS revealed that 100% of the BCP-ALL
patients showed at least one genetic alteration at diagnosis and relapse. In addition, there was
a significant increase in the frequency of chromosomal lesions at the time of relapse (p = 0.019).
MLPA and aCGH techniques showed that IKZF1 was the most frequently deleted gene. TP53 was the
most frequently mutated gene at relapse. Two TP53 mutations were detected only at relapse, whereas
the three others showed an increase in their mutational burden at relapse. Clonal evolution patterns
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were heterogeneous, involving the acquisition, loss and maintenance of lesions at relapse. Therefore,
this study provides additional evidence that BCP-ALL is a genetically dynamic disease with distinct
genetic profiles at diagnosis and relapse. Integrative NGS, aCGH and MLPA analysis enables better
molecular characterization of the genetic profile in BCP-ALL patients during the evolution from
diagnosis to relapse.
Keywords: acute lymphoblastic leukemia (ALL); relapse; next-generation sequencing (NGS); array
comparative genomic hybridization (aCGH); multiplex ligation-dependent probe amplification
(MLPA); IKZF1; TP53
1. Introduction
Acute lymphoblastic leukemia (ALL) is a disease with specific genetic alterations associated
with drug resistance, treatment failure and disease relapse [1,2]. Despite vast improvements in the
treatment of childhood and adult ALL in recent years, the outlook for relapsed leukemia remains poor,
highlighting the need for innovative treatment approaches [3]. It is well known that relapsed ALL is
a heterogeneous disease and that distinct genetic alterations may be unique to small subgroups of
patients [3]. Genomic studies of matched diagnosis–relapse samples from ALL patients have shed light
on the clonal evolution that leads to relapse, the pathways associated with chemoresistance, and the
potential targets for therapy [4–9]. However, the mechanisms that probably fuel an ALL relapse are not
fully understood. A combined analysis of gene mutations and copy number alterations (CNAs) could
provide valuable insight into the discovery of the patterns of clonal evolution and the biomarkers that
predict a greater likelihood of relapse in ALL [3,10,11]. Here, we have performed an integrated and
sequential genomic analysis combining next-generation sequencing (NGS), array comparative genomic
hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) to identify the
clonal shifts related to ALL progression.
2. Materials and Methods
2.1. Patients
Thirteen paired diagnosis and first relapse samples of B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) patients (4 children and 9 adults) were eligible for this study. The patients
were treated in accordance with the risk-adapted protocols of PETHEMA (Programa Español de
Tratamientos en Hematología) and SEHOP (Sociedad Española de Hematología y Oncología Pediátrica).
The diagnosis of ALL was based on morphological, immunophenotypic and genetic features of leukemic
blast cells, as described previously [12]. The patients’ demographic information, clinical characteristics,
risk classification, response to therapy and survival were recorded. The study was approved by the
local ethical committee, the Comité Ético de Investigación Clínica, at the Hospital Universitario de
Salamanca. Written informed consent was obtained from each patient or their legal guardian before
entering the study.
Table 1 shows the characteristics of the patients included in this study. The median age was
31 years (range 4–80 years). The median percentage of blast counts in their bone marrow was 82%
(range 45–96%). Fifty-four per cent of the patients had none of the chromosomal abnormalities
associated with poor risk (t(9;22), t(v;11q23) or hypodiploidy). Ninety-two per cent of patients died
presenting a 5-year overall survival probability of 15% (median: 22 months, 95% CI: 3.2–40.8 (Table 1
and Table S1)).
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Table 1. Characteristics of the patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
included in the study.
Characteristics Patients (n = 13)
Age at diagnosis (years), median (range) 31 (4–80)
Male/Female, (%) 3/10 (23.1/76.9)
Bone marrow blast 1, median (range) 82 (45–96)
White blood cell count (×109/L), median (range) 27 (3–168)
Hb count (g/L), median (range) 105 (39–160)
Platelet count (×109/L), median (range) 73 (29–248)
Elevated LDH, (U/L) level, (%) 66.7
Cytogenetics
Poor risk 2 (%) 46.2
Others (%) 53.8
Risk group 3
Low risk (%) 7.7
Intermediate risk (%) 23.1
High risk (%) 69.2
Time to relapse
Very early relapse 4 (%) 53.8
Early relapse 4 (%) 15.4
Late relapse 4 (%) 30.8
5-year overall survival probability % (median, 95% CI) 15.3 (22, 3.2–40.8)
1 Estimated by flow cytometry. 2 Includes the unfavorable abnormalities t(9;22), t(v;11q23) and hypodiploidy. 3 Risk
group stratification was mainly designated according to the Programa Español de Tratamientos en Hematología
(PETHEMA) protocols. 4 Time of relapse criteria: very early, earlier than 18 months after initial diagnosis and
less than 6 months after the cessation of frontline treatment; early, more than 18 months after initial diagnosis,
but less than 6 months after the cessation of frontline treatment; late, more than 6 months after the cessation of
frontline treatment.
2.2. DNA Isolation and Next-Generation Sequencing Assay (NGS)
Genomic DNA was extracted from frozen fixed bone marrow cell samples with a QIAmp DNA
Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. The mutational
status of the JAK2 (exons 12 to 16), PAX5 (exons 2 and 3), LEF1 (exons 2 and 3), CRLF2 (exon 6), IL7R
(exon 5) and TP53 (exons 4–11) genes was investigated using two preconfigured 96-well primer plates
(Roche, Branford, CT, USA) with titanium amplicon chemistry (454 Life Sciences, Branford, CT, USA).
The above-mentioned genes were selected due to their well-defined roles as mutational hot spots
in BCP-ALL [13–23]. A variant analysis was performed using GS Amplicon Variant Analyzer 2.5.3
(454 Life Sciences, Roche Applied Science) and Sequence Pilot version 3.4.2 (JSI Medical Systems,
Kippenheim, Germany) software [24,25]. The variants were filtered to display the sequence variants
occurring in more than 2% of bidirectional reads per amplicon in at least one patient [26–28]. All somatic
mutations were searched on the online COSMIC database—Catalogue of Somatic Mutations in Cancer
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic) and the IARC TP53 database—International
Agency for Research on Cancer (http://p53.iarc.fr/p53Sequences.aspx) [29]. The sequence variations
identified by NGS were independently validated using conventional Sanger sequencing and/or a
separate setup of the NGS re-sequencing run.
2.3. Oligonucleotide Array Comparative Genomic Hybridizations (Array-CGH)
All samples were tested on an aCGH 12X135K array platform (Roche NimbleGen,
Madison, WI, USA). Raw log2 ratios were segmented using the copy number R package (version
1.20.0) [30]. We used the GISTIC algorithm—(version 2.0.23) to identify statistically significant minimal
common altered regions (MCRs) and the broad CNAs present in the samples [31]. The Database of
Genomic Variants from Toronto (DGV, http://dgv.tcag.ca/dgv/app/home) was used to exclude DNA
variations located in regions with defined copy number variations. All CNAs with an overlap of more
than 50% with respect to those reported in the DGV were excluded.
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2.4. Multiplex Ligation-Dependent Probe Amplification (MLPA)
MLPA reactions were performed using the SALSA MLPA P335-B1 ALL-IKZF1 probemix
(MRC-Holland, Amsterdam, Netherlands) according to the manufacturer’s instructions. DNA samples
from three healthy donors were used as controls. The P335-B1 probemix contains probes for the
following genes: IKZF1, CDKN2A/B, PAX5, EBF1, ETV6, BTG1, RB1, as well as genes from the X/Y
PAR1 region (CRLF2, CSF2RA, IL3RA and P2RY8). MLPA amplification products were analyzed on an
ABI 3130xl Genetic Analyzer (Applied Biosystems/Hitachi) with GeneMapper software V.3.7, using the
Genescan 500LIZ internal size standard (Applied Biosystems). The copy number at each locus was
estimated according to Schwab et al. [32].
According to the probemix contained in the P335-B1 MLPA kit, an integrative MLPA–aCGH
analysis was performed to identify gene deletions in the IKZF1, CDKN2A/B, PAX5, EBF1, ETV6, BTG1
and RB1 genes, as well as genes from the X/Y PAR1 region (CRLF2, CSF2RA, IL3RA and P2RY8). The copy
number at each locus was estimated according to the method of Schwab et al. [32], whereby values
above 1.3, between 1.3 and 0.75, between 0.75 and 0.25, and below 0.25 were considered as gain, normal,
hemizygous loss, and homozygous loss, respectively. It was possible to distinguish the gene deletions
identified either by MLPA or by aCGH analysis, or by the both methods. The distributions of the
probes in each platform are illustrated in Figure S1.
2.5. Statistical Methods
The differences between groups were compared by the chi-square, Fisher’s exact,
and Mann–Whitney tests, as appropriate. Values of p < 0.05 were considered to be statistically
significant. Analyses were conducted using IBM SPSS version 21.0 (IBM Corp., Armonk, NY, USA).
The materials, procedures and statistical analyses are described in detail in the Supplementary
File 1.
3. Results
3.1. Recurring Genomic Alterations in Matched Diagnosis–Relapse BCP-ALL Samples
The aCGH detected 1451 somatic genetic lesions in 13 paired (diagnosis and relapse) BCP-ALL
samples. The number of genetic lesions varied significantly between patients (1–287 lesions; median,
16 per sample). There were no significant differences in the number of CNAs between children and
adults (p = 0.765), or between patients who had early relapses and those who did not (p = 0.731).
Figures 1 and 2 and Figure S2 show the main aCGH findings at diagnosis and relapse, with a significant
increase in the number of lesions at relapse. There was a median of six alterations per sample at
diagnosis and of 47 at relapse (p = 0.019).
Figures 1 and 2 and Figure S2 show the patterns and frequencies of DNA copy alterations observed
in the 13 paired diagnosis/relapse samples. The most recurrent broad and focal copy number changes
observed at diagnosis and/or relapse were: dup(1q) at 23%, dup(X) at 31%, dup(21) at 15%, del(7 or 7p)
at 77%, dup(7q) at 31%, del(9p) at 62%, del(12p) at 15%, del(13q) at 23% and del(17p) at 15%. Of these,
the deletions located on 7p and 9p were the most frequently focal and broad chromosomal alterations
detected at diagnosis and/or relapse (77% and 62%, respectively (Table S1)).
Our integrative MLPA–aCGH analysis showed that the percentages of deleted genes in the
following paired diagnosis/relapse BCP-ALL samples were: IKZF1, 54% vs. 62%, p = 0.691; CDKN2A/B,
54% vs. 23%, p = 0.107; PAX5, 38% vs. 23%, p = 0.673; EBF1, 23% vs. 15%, p = 1.000; BTG1, 23% vs.
23%, p = 1.000; ETV6, 15% vs. 15%, p = 1.000; RB1, 8% vs. 15%, p = 1.000, and PAR1, 15% vs. 8%,
p = 1.0. Thus, no statistically significant differences in the frequency of these gene deletions were found
between diagnosis and relapse. Figure 3 compares the main complementary findings at the two points
in disease evolution by MLPA and/or aCGH techniques.
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Figure 3. Gene deletions identified by an integrative LPA–aCG analysis. ** The P335-B1 probe ix
contains probes for the following genes: IKZF1 (eight probes at 7p12.2), CDKN2A/B (three probes at
9p21.3), PAX5 (seven probes at 9p13.2), EBF1 (four probes at 5q33.3), ETV6 (six probes at 12p13.2),
four probes for BTG1 and the BTG1 downstream region (at 12q21.33), RB1 (five probes at 13q14.2),
as well as genes from the X/Y PAR1 region (CRLF2, CSF2RA, IL3RA and P2RY8 (five probes at Xp22.33)).
Additionally, there is one probe at Yp11.31 (ZFY) and one at 9p24.1.
A NGS analysis revealed six mutations in 4/13 (31%) patients (three children: ID2, ID3, ID4,
and one adult: ID7)) at diagnosis and/or relapse. Notably, three of them (ID2, ID3 and ID4) did not
have poor risk cytogenetics at diagnosis. Likewise, it should be mentioned that two of them were
treated at diagnosis with high risk protocols (ID2 and ID7), one with an intermediate risk protocol (ID4)
and one with a low risk protocol (ID3 (Table S1)). Of these six mutations, a sequence analysis revealed
three missense mutations, one splicing site mutation and two deletion-insertions. TP53 was the most
frequently mutated gene (4/13, 31%), whereas PAX5 was only mutated in one adult patient (ID7 (1/13,
8%)). Interestingly, two TP53 mutations were only detected at relapse (ID3: c.829_842delins14 and
ID7: c.-8_4del12), whereas the remaining were present from diagnosis and maintained at relapse (ID2:
817_821delinsGACCC, ID4: c.832C > T, ID7: c.818G > C (Table 2)).
The complementary integrative genomic analysis using aCGH, MLPA and NGS revealed that
100% of ALL patients showed at least one genetic alteration at diagnosis and relapse (mutation, loss
and/or gain, or chromosomal rearrangement identified by Fluorescence in situ hybridization (FISH)
). The frontline risk-adapted protocols, outcome, clinical status, karyotype, FISH, NGS, aCGH and
MLPA analysis of each patient are shown in Table S1.
3.2. Heterogeneous Patterns of Genetic Evolution in Paired Diagnosis and Relapse Samples
Tables S2–S4 show the regions of statistically significant recurrent amplification and deletion that
were retained, lost, or acquired as new lesions at relapse, respectively (q-value < 0.05).
The statistically significant peaks retained at relapse included gains on 10q26.13 (FAM53B), 15q11.2
and losses on 1p36.32, 5p15.33, 9p21.3 (PTPLAD2, MLLT3), 9p21.2 (CDKN2A, CDKN2B, DMRTA1)
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and 10q26.3. The significant peaks lost at relapse included losses on 8q24.3 and 19p13.3 (TCF3, E2A).
Finally, the significant peaks acquired as new lesions at relapse included gains on 1p36, 1q21, 2p13.3
(DYSF), 3q21, 4p16, 5q33.1 (PDGFRB), 7q36.1 (EZH), 10q25.2, (ADD3), 14q32.31 (BCL11B), and losses
on 9q34.2 and 13q34.
Table 2. Description of somatic mutations observed in diagnosis–relapse BCP-ALL patients. All three
TP53 mutations retained at relapse increased their mutational burden to relapse (c.818G > C from 3.5%
to 26%, c.832C > T from 11% to 21% and 817_821delinsGACCC from 53% to 71%).
Patient
ID Gene
Type of
Mutation Mutation AA Change Database Moment
Mutational
Burden
ID2 TP53-E08 Indel c.817_821delinsGACCC p.R273_V274delinsDP Undescribed
Diagnosis 53%
Relapse 71%
ID4 TP53-E08 Missense c.832C > T p.P278S
COSM10939/TP53
website http://p53.fr/
Diagnosis 11%
Relapse 21%
ID7
PAX5-E03 Missense c.399T > A p.S133R Undescribed Diagnosisonly 20%
TP53-E08 Missense c.818G > C p.R273P
COSM165077/TP53
website http://p53.fr
Diagnosis 3.5%
Relapse 26%
TP53-E05 Splicing c.-8_4del12 Splice_Intron 5 SA TP53 websitehttp://p53.fr
Relapse
only 15%
ID3 TP53-E05 Missense c.829_842delins14 p.C277_D281delinsGPQG Undescribed Relapseonly 90%
An integrative analysis showed that all patients exhibited heterogeneous changes in the pattern
of CNAs from diagnosis to relapse, indicating that the profile of the relapse samples was genomically
distinct: 8% of patients acquired only new genetic lesions at relapse, 38% of patients acquired new
lesions and lost lesions present at diagnosis, and 54% of the patients simultaneously retained, lost and
acquired lesions at relapse (Figures 2–4).
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Diagnostics 2020, 10, 455 8 of 13
The MLPA–aCGH analysis revealed that most of the patients (5/7, 71%) with deletions of IKZF1
(7p) at diagnosis retained this genetic alteration at relapse (children: ID1 and ID4, and adults: ID6, ID9
and ID12). By contrast, only three (ID2, ID9, ID12) of seven patients (42.9%) with CDKN2A/B and/or
PAX5 deletions (9p) retained these deletions at relapse. It should be noted that the adult patient ID13,
who presented an elevated number of CNAs at relapse, acquired new lesions in the chromosomal
regions that harbored the EBF1, CDKN2A/B, IKZF1, BTG1 and RB1 genes. Finally, the losses on 17p
were also identified in two patients (child ID2 and adult ID9) at diagnosis, being retained at relapse
in child ID2. An insertion/deletion mutation in TP53 was also identified in this pediatric patient at
diagnosis and relapse (Tables S1 and S2, Figures 1, 3 and 4).
Table 2 details the mutations observed at both times and describes their mutational burden.
Interestingly, two TP53 mutations were acquired at relapse (ID3, ID7), whereas all three TP53 mutations,
which were detected from diagnosis, had an increase in their mutational burden at relapse (ID2, ID4,
ID7 (Figure 5)). Thus, in the pediatric patient ID2, an increase in the TP53 mutant clone burden was
observed at relapse (53% to 71%), as well as in the pediatric patient ID4 (11% to 21%) and the adult
patient ID7 (3.5% to 26%), respectively.
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better molecular characterization of the genetic profile in ALL patients during the evolution of their
disease from diagnosis to relapse.
4. Discussion
The present study, carried out in sequential ALL patients at diagnosis and relapse, showed
that all 13 ALL patients exhibited heterogeneous clonal changes in terms of CNAs and mutations
between diagnosis and relapse, involving the acquisition, loss and maintenance of lesions at relapse.
The shared lesions between the relapse clone and the predominant clone at diagnosis suggest a common
pre-leukemic origin [22], while the acquired lesions provide unequivocal evidence of a second clone
that was present as a minor population at diagnosis, but acquired different genetic alterations before
emerging as the relapse clone [5].
An integrated NGS, aCGH, and MLPA analysis allowed for the identification of alterations on the
IKZF1 (7p) and TP53 (17p) genes in paired diagnostic and relapse samples; these were more frequent at
relapse than at diagnosis. Both genetic events could have strongly influenced disease relapse and the
short survival of these patients. In this study, TP53 is the most frequently mutated gene at relapse (31%).
TP53 abnormalities (deletion and/or mutation) have been associated with a resistance to treatment
and worse prognosis in childhood and adult ALL [8,33]. TP53 gene abnormalities have a key role in
ALL relapse, as they independently predict a high risk of treatment failure in ALL patients [8,24,34].
The presence of TP53 alterations has been associated with a reduced response rate to induction therapy
and correlated with a shortened duration of survival, even after successful reinduction therapy [35,36].
Different therapeutic strategies to target mutant p53 have been developed for the high risk TP53-mutant
ALL, such as the use of the small molecule APR-246 which exhibits antileukemia activity in TP53mut
BCP-ALL, targeting non-functional mutant p53 and restoring its tumor suppressive function [37].
IKZF1 was the most frequently deleted gene, the incidence of deletions being greater at relapse
than at diagnosis. Similarly, as seen in previous studies, the frequency of IKZF1 deletions was higher
in adults than in children [38]. IKZF1 deletions have been associated with a higher risk of relapse
in ALL and have been shown to be a hallmark of BCR-ABL1-positive ALL, although they have also
been identified in a fraction of BCR-ABL1-negative ALL patients [10,38–43], as noted in our study.
In recent years, IKZF1 deletions and TP53 alterations are being recognized as important markers of poor
prognosis in ALL after a first relapse, mainly in children [9,39,44]. Therefore, these alterations could
contribute to the re-stratification of risk for ALL patients and to proposing timely therapeutic strategies
such as treatment intensification and identifying candidates for transplantation or for inclusion in
clinical trials due to their high risk of suffering a second relapse [34,45,46].
In the present study, heterogeneous patterns of genetic evolution in paired diagnostic and relapse
samples were observed that are consistent with those reported in previous studies [47]. In particular,
two TP53 mutations were only detected at relapse (patients ID3 and ID7), whereas all three TP53
mutations increased their mutational burden between diagnosis and relapse (patients ID2, ID4 and
ID7). It should be noted that two of the six TP53 mutations identified had not been reported in the
genomic databases.
ALL is clonally heterogeneous and genetic lesions in minor clones may confer resistance to
therapy and promote disease relapse (e.g., TP53, IKZF1, CREBBP) [22]. The low proportion of the
minor relapse subclone at diagnosis suggests that the leukemia at diagnosis contains genetically
diverse subclones. Therapy would aim to select the eventual dominant relapse clone whose alterations
confer resistance to treatment [48]. Thus, TP53 mutations could be considered as driver mutations
that probably confer a selective growth advantage on ALL tumor cells at relapse [24]. Preclinical
studies and clinical experience have shown that leukemic blasts are more resistant at relapse than at
diagnosis. Mechanisms of resistance may include the selection of a pre-existing resistant subclone or
the acquisition of additional genomic lesions under the selective pressure of chemotherapy, as observed
in our study [4].
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5. Conclusions
In summary, the present study provides additional evidence that the clonality of ALL is genetically
dynamic from diagnosis to relapse. The integrative NGS, aCGH, and MLPA analysis enabled a better
molecular characterization of the genetic profile in ALL patients during the evolution of their disease,
showing distinct genetic profiles at diagnosis and relapse. With this study, the utility of simultaneously
identifying CNAs and mutations at the time of diagnosis and relapse was evidenced, which is clinically
important to predict the evolution of the patients. New genomic strategies to identify various genetic
lesions from a single sample and in a single experiment are currently being solved by designing
specific panels for each type of hematological disease, which contribute to the improvement of the risk
stratification, promoting the use of personalized treatment in ALL.
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